Beta Bionics has set the terms for its plan to go public, with a goal of raising at least $114 million to support its artificial pancreas system for people with Type 1 diabetes. | The company is set to begin trading on the Nasdaq between $14 and $16 per share—a range that would give Beta Bionics about a $625 million valuation.
Artificial pancreas maker Beta Bionics aims to raise $120M in Nasdaq IPO
Date:
More like thisRelated
Tampa RV giant Lazydays to delist from Nasdaq
Tampa-based Lazydays Holdings Inc., one of Florida’s most recognized...
Granite Geek: New Hampshire might get access to ‘balcony solar’
I had solar panels put on my roof six...
TSX Today: What to Watch for in Stocks on Monday, November 10
Despite firm gold and silver prices, Canadian stocks...
While BNB and DOT Struggle Under Market Pressure, BlockDAG’s Presale Soars Past $435M!
As market-wide fear grips the sector, the Binance Coin...